Watanabe T | Tokyo Univ. Tokyo

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy
Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy : case report and review of the literature
Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma
Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma : morphological, immunohistochemical, and FISH analyses
Nocardia exalbida brain abscess in a patient with follicular lymphoma
Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
Phase I Study of Intravenous PSC-833 and Doxorubicin: Reversal of Multidrug Resistance
Suppressive Effect of Irsogladine Maleate on Diethylnitrosamine-initiated and Phenobarbital-promoted Hepatocarcinogenesis in Male F344 Rats
Chemopreventive Effects of Scordinin on Diethylnitrosamine and Phenobarbital-induced Hepatocarcinogenesis in Male F344 Rats
Modulating Effects of Diets High in ω-3 and ω-6 Fatty Acids in Initiation and Postinitiation Stages of Diethylnitrosamine-induced Hepatocarcinogenesis in Rats
Suppressive Effects of S-Methyl Methanethiosulfonate on Promotion Stage of Diethylnitrosamine-initiated and Phenobarbital-promoted Hepatocarcinogenesis Model
Inhibitory Effect of Chlorophyllin on Diethylnitrosamine and Phenobarbital-induced Hepatocarcinogenesis in Male F344 Rats
Chemopreventive Effects of Taurine on Diethylnitrosamine and Phenobarbitalinduced Hepatocarcinogenesis in Male F344 Rats
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (^Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma
t(11 ; 18)-Bearing Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Responding to Cladribine
Two Entities of Precursor T-Cell Lymphoblastic Leukemia/Lymphoma Based on Radiologic and Immunophenotypic Findings
Primary Mediastinal Large B-Cell Lymphoma : A Single-Institution Clinical Study in Japan
EBV-Positive Burkitt Lymphoma as a Late-Onset Posttransplantion Lymphoproliferative Disorder after Allogeneic Stem Cell Transplantation
Primary Hepatic Low-Grade B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type : A Case Report and Review of the Literature
Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma
Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia : a single-center analysis of 47 patients
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
Pharmacodynamic Modeling of the Entire Time Course of Leukopenia after a 3-Hour Infusion of Paclitaxel
Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with
Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma : 7-year follow-up results
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma

もっと見る

スポンサーリンク